| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycomb Repressive Complex 1 | 9 | 2018 | 34 | 3.590 |
Why?
|
| Ovarian Neoplasms | 23 | 2025 | 610 | 2.820 |
Why?
|
| Metal Nanoparticles | 26 | 2025 | 137 | 2.400 |
Why?
|
| Cystathionine beta-Synthase | 7 | 2023 | 31 | 2.350 |
Why?
|
| Antineoplastic Agents | 18 | 2020 | 685 | 2.330 |
Why?
|
| Gold | 30 | 2025 | 137 | 1.990 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2017 | 140 | 1.570 |
Why?
|
| Cell Line, Tumor | 35 | 2025 | 1362 | 1.280 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2024 | 172 | 1.280 |
Why?
|
| Vascular Endothelial Growth Factor A | 12 | 2019 | 179 | 1.170 |
Why?
|
| Cell Proliferation | 26 | 2024 | 828 | 1.160 |
Why?
|
| Cell Movement | 16 | 2024 | 378 | 1.090 |
Why?
|
| Hydrogen Sulfide | 4 | 2023 | 33 | 0.960 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2024 | 473 | 0.950 |
Why?
|
| DNA Damage | 4 | 2022 | 153 | 0.930 |
Why?
|
| Humans | 76 | 2025 | 29211 | 0.920 |
Why?
|
| Signal Transduction | 15 | 2024 | 1502 | 0.920 |
Why?
|
| Neoplasm Proteins | 4 | 2019 | 123 | 0.890 |
Why?
|
| Carcinosarcoma | 3 | 2025 | 31 | 0.880 |
Why?
|
| MicroRNAs | 4 | 2024 | 305 | 0.870 |
Why?
|
| Apoptosis | 10 | 2018 | 784 | 0.870 |
Why?
|
| Nanoparticles | 9 | 2024 | 292 | 0.850 |
Why?
|
| Uterine Neoplasms | 3 | 2025 | 80 | 0.850 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2022 | 9 | 0.840 |
Why?
|
| Mitochondria | 7 | 2020 | 419 | 0.840 |
Why?
|
| Neovascularization, Pathologic | 9 | 2019 | 148 | 0.840 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 9 | 2019 | 59 | 0.830 |
Why?
|
| Cisplatin | 8 | 2024 | 186 | 0.820 |
Why?
|
| Endothelium, Vascular | 6 | 2020 | 347 | 0.820 |
Why?
|
| Animals | 38 | 2025 | 10806 | 0.810 |
Why?
|
| Homeostasis | 2 | 2016 | 122 | 0.790 |
Why?
|
| Autophagy | 3 | 2021 | 77 | 0.760 |
Why?
|
| Astrocytes | 1 | 2023 | 80 | 0.750 |
Why?
|
| Rad51 Recombinase | 1 | 2022 | 11 | 0.750 |
Why?
|
| Transcription, Genetic | 4 | 2019 | 406 | 0.710 |
Why?
|
| Neoplasms | 6 | 2020 | 888 | 0.710 |
Why?
|
| Drug Delivery Systems | 9 | 2025 | 236 | 0.700 |
Why?
|
| Disease | 2 | 2020 | 15 | 0.690 |
Why?
|
| Protein Kinases | 1 | 2022 | 164 | 0.680 |
Why?
|
| Mice, Nude | 14 | 2024 | 333 | 0.680 |
Why?
|
| Physiological Phenomena | 1 | 2020 | 2 | 0.660 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2020 | 14 | 0.660 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2020 | 6 | 0.640 |
Why?
|
| Mice | 23 | 2025 | 4870 | 0.640 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 59 | 0.630 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2024 | 276 | 0.630 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 4 | 2019 | 65 | 0.620 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 137 | 0.610 |
Why?
|
| Pancreatic Neoplasms | 9 | 2020 | 556 | 0.600 |
Why?
|
| Nanomedicine | 6 | 2024 | 62 | 0.600 |
Why?
|
| Repressor Proteins | 2 | 2011 | 120 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 166 | 0.580 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 249 | 0.560 |
Why?
|
| Female | 28 | 2025 | 15825 | 0.550 |
Why?
|
| Epithelial-Mesenchymal Transition | 5 | 2024 | 123 | 0.540 |
Why?
|
| Brain | 1 | 2023 | 774 | 0.540 |
Why?
|
| Tumor Microenvironment | 5 | 2020 | 205 | 0.540 |
Why?
|
| Pyrazines | 1 | 2017 | 26 | 0.530 |
Why?
|
| Benzimidazoles | 1 | 2017 | 32 | 0.530 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 285 | 0.510 |
Why?
|
| Histone Acetyltransferases | 2 | 2016 | 15 | 0.500 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 189 | 0.490 |
Why?
|
| Drug Resistance, Multiple | 1 | 2016 | 20 | 0.480 |
Why?
|
| Gene Silencing | 4 | 2020 | 65 | 0.480 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 33 | 0.460 |
Why?
|
| Aging | 1 | 2023 | 1041 | 0.460 |
Why?
|
| Tumor Cells, Cultured | 5 | 2019 | 314 | 0.460 |
Why?
|
| Transfection | 9 | 2015 | 319 | 0.460 |
Why?
|
| Nanoconjugates | 5 | 2020 | 18 | 0.440 |
Why?
|
| Endothelial Cells | 9 | 2024 | 377 | 0.440 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 79 | 0.430 |
Why?
|
| Neovascularization, Physiologic | 4 | 2019 | 127 | 0.410 |
Why?
|
| Nanotechnology | 7 | 2020 | 68 | 0.400 |
Why?
|
| Cell Differentiation | 1 | 2016 | 430 | 0.400 |
Why?
|
| Phosphorylation | 6 | 2019 | 586 | 0.400 |
Why?
|
| Protein Binding | 7 | 2019 | 667 | 0.390 |
Why?
|
| Phospholipase C beta | 2 | 2012 | 4 | 0.390 |
Why?
|
| DNA Repair | 3 | 2022 | 83 | 0.380 |
Why?
|
| Cells, Cultured | 10 | 2020 | 1024 | 0.380 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 417 | 0.380 |
Why?
|
| Cation Transport Proteins | 3 | 2020 | 60 | 0.370 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2012 | 1 | 0.360 |
Why?
|
| Phosphoproteins | 1 | 2012 | 120 | 0.340 |
Why?
|
| Models, Biological | 6 | 2020 | 471 | 0.330 |
Why?
|
| Caspases | 3 | 2018 | 43 | 0.300 |
Why?
|
| Veratrum Alkaloids | 1 | 2008 | 4 | 0.290 |
Why?
|
| Hedgehog Proteins | 1 | 2008 | 35 | 0.280 |
Why?
|
| Naphthoquinones | 2 | 2012 | 11 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 336 | 0.280 |
Why?
|
| Gene Knockdown Techniques | 7 | 2019 | 134 | 0.270 |
Why?
|
| Histones | 2 | 2019 | 96 | 0.270 |
Why?
|
| Cell Survival | 3 | 2020 | 422 | 0.270 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 3 | 2020 | 23 | 0.260 |
Why?
|
| Calcium-Binding Proteins | 3 | 2020 | 62 | 0.260 |
Why?
|
| Dynamin II | 2 | 2010 | 13 | 0.250 |
Why?
|
| Zebrafish | 3 | 2020 | 107 | 0.240 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 165 | 0.230 |
Why?
|
| Endocytosis | 4 | 2025 | 97 | 0.230 |
Why?
|
| Gene Transfer Techniques | 1 | 2025 | 75 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2012 | 108 | 0.220 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2004 | 8 | 0.220 |
Why?
|
| Trans-Activators | 1 | 2005 | 118 | 0.220 |
Why?
|
| Aged | 4 | 2025 | 5648 | 0.210 |
Why?
|
| Drug Carriers | 4 | 2020 | 119 | 0.210 |
Why?
|
| RNA, Messenger | 2 | 2025 | 669 | 0.200 |
Why?
|
| Cystathionine | 1 | 2023 | 6 | 0.200 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 32 | 0.200 |
Why?
|
| Pinocytosis | 2 | 2021 | 17 | 0.200 |
Why?
|
| Protein Kinase C | 2 | 2019 | 74 | 0.200 |
Why?
|
| Cell Nucleus | 2 | 2019 | 138 | 0.200 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 466 | 0.200 |
Why?
|
| Glutathione | 2 | 2015 | 77 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 349 | 0.190 |
Why?
|
| DNA Polymerase II | 1 | 2002 | 1 | 0.190 |
Why?
|
| Exodeoxyribonucleases | 1 | 2002 | 6 | 0.190 |
Why?
|
| Recombinational DNA Repair | 1 | 2022 | 7 | 0.190 |
Why?
|
| Blotting, Western | 4 | 2013 | 515 | 0.190 |
Why?
|
| Platinum | 3 | 2012 | 18 | 0.180 |
Why?
|
| Silver | 3 | 2012 | 21 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 434 | 0.170 |
Why?
|
| Clathrin | 1 | 2021 | 20 | 0.170 |
Why?
|
| Escherichia coli Proteins | 1 | 2002 | 120 | 0.170 |
Why?
|
| Paclitaxel | 2 | 2025 | 201 | 0.160 |
Why?
|
| Oxidative Stress | 3 | 2020 | 692 | 0.160 |
Why?
|
| Phototherapy | 1 | 2021 | 28 | 0.160 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 108 | 0.160 |
Why?
|
| Up-Regulation | 2 | 2019 | 247 | 0.160 |
Why?
|
| Glycolysis | 2 | 2020 | 96 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 344 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 3 | 2019 | 96 | 0.160 |
Why?
|
| Mitochondrial Dynamics | 1 | 2020 | 18 | 0.160 |
Why?
|
| Calcium | 6 | 2017 | 244 | 0.160 |
Why?
|
| Protein Corona | 1 | 2020 | 9 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 62 | 0.160 |
Why?
|
| Histone Deacetylase 1 | 1 | 2019 | 10 | 0.160 |
Why?
|
| Histone Deacetylase 2 | 1 | 2019 | 10 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2002 | 342 | 0.150 |
Why?
|
| Mutation | 3 | 2017 | 875 | 0.150 |
Why?
|
| Transcription Factor AP-2 | 1 | 2019 | 5 | 0.150 |
Why?
|
| RNA, Small Interfering | 4 | 2020 | 198 | 0.150 |
Why?
|
| Cell Cycle | 3 | 2015 | 163 | 0.150 |
Why?
|
| Hypoxia | 1 | 2020 | 90 | 0.150 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 481 | 0.150 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2019 | 10 | 0.150 |
Why?
|
| Apelin Receptors | 1 | 2019 | 11 | 0.150 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 1524 | 0.150 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2020 | 178 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2020 | 256 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 485 | 0.140 |
Why?
|
| Adenosine Triphosphate | 2 | 2016 | 121 | 0.140 |
Why?
|
| Cell Membrane | 3 | 2010 | 268 | 0.140 |
Why?
|
| ErbB Receptors | 4 | 2011 | 100 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 329 | 0.130 |
Why?
|
| Endosomes | 3 | 2025 | 53 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2018 | 80 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2017 | 5 | 0.130 |
Why?
|
| Casein Kinase II | 1 | 2017 | 17 | 0.130 |
Why?
|
| Deoxycytidine | 3 | 2020 | 67 | 0.130 |
Why?
|
| Proteolysis | 1 | 2017 | 60 | 0.120 |
Why?
|
| Lysine Acetyltransferase 5 | 1 | 2016 | 4 | 0.120 |
Why?
|
| Acetylation | 1 | 2016 | 41 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2019 | 202 | 0.120 |
Why?
|
| Cetuximab | 5 | 2020 | 22 | 0.120 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2016 | 3 | 0.120 |
Why?
|
| Doxorubicin | 1 | 2016 | 78 | 0.120 |
Why?
|
| Mice, Knockout | 2 | 2016 | 881 | 0.120 |
Why?
|
| Neuropilins | 1 | 2015 | 4 | 0.120 |
Why?
|
| Second Messenger Systems | 1 | 2015 | 13 | 0.120 |
Why?
|
| Lipogenesis | 1 | 2015 | 29 | 0.120 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2070 | 0.110 |
Why?
|
| Necrosis | 1 | 2016 | 85 | 0.110 |
Why?
|
| Thiazoles | 1 | 2016 | 50 | 0.110 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2015 | 25 | 0.110 |
Why?
|
| Triglycerides | 1 | 2015 | 123 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 142 | 0.110 |
Why?
|
| Survival Rate | 1 | 2016 | 433 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2020 | 267 | 0.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 153 | 0.110 |
Why?
|
| Risk Factors | 1 | 2019 | 2144 | 0.100 |
Why?
|
| Reactive Oxygen Species | 2 | 2018 | 303 | 0.100 |
Why?
|
| Cholesterol | 1 | 2015 | 204 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2016 | 272 | 0.100 |
Why?
|
| Microscopy, Electron, Transmission | 5 | 2013 | 82 | 0.100 |
Why?
|
| Golgi Apparatus | 2 | 2010 | 26 | 0.100 |
Why?
|
| Disease Progression | 3 | 2024 | 483 | 0.100 |
Why?
|
| Zebrafish Proteins | 2 | 2012 | 21 | 0.100 |
Why?
|
| Prognosis | 1 | 2016 | 817 | 0.100 |
Why?
|
| Middle Aged | 3 | 2025 | 7495 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 2 | 2005 | 163 | 0.100 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2011 | 29 | 0.100 |
Why?
|
| Designer Drugs | 1 | 2013 | 2 | 0.100 |
Why?
|
| Particle Size | 5 | 2014 | 105 | 0.100 |
Why?
|
| Adult | 3 | 2025 | 8130 | 0.090 |
Why?
|
| Cytokines | 2 | 2005 | 457 | 0.090 |
Why?
|
| Cell Division | 2 | 2002 | 154 | 0.090 |
Why?
|
| Proteins | 2 | 2020 | 256 | 0.090 |
Why?
|
| Cell Line | 4 | 2019 | 705 | 0.090 |
Why?
|
| Protein Transport | 2 | 2010 | 158 | 0.090 |
Why?
|
| Umbilical Veins | 3 | 2009 | 25 | 0.090 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2012 | 25 | 0.090 |
Why?
|
| Capillary Permeability | 1 | 2012 | 56 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 67 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 120 | 0.090 |
Why?
|
| Tissue Distribution | 3 | 2022 | 137 | 0.090 |
Why?
|
| Drug Design | 1 | 2011 | 63 | 0.080 |
Why?
|
| Surface Properties | 4 | 2014 | 134 | 0.080 |
Why?
|
| Qa-SNARE Proteins | 1 | 2010 | 7 | 0.080 |
Why?
|
| Biological Transport | 3 | 2021 | 128 | 0.080 |
Why?
|
| Lysosomes | 3 | 2021 | 56 | 0.080 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 18 | 0.080 |
Why?
|
| Chemotaxis | 1 | 2010 | 28 | 0.080 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 34 | 0.080 |
Why?
|
| Carboplatin | 2 | 2025 | 121 | 0.080 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2009 | 34 | 0.080 |
Why?
|
| Dopamine | 1 | 2009 | 24 | 0.080 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 301 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2009 | 15 | 0.070 |
Why?
|
| Immunoprecipitation | 2 | 2009 | 68 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2010 | 58 | 0.070 |
Why?
|
| Inositol Phosphates | 1 | 2009 | 6 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2011 | 153 | 0.070 |
Why?
|
| Phosphoserine | 1 | 2009 | 10 | 0.070 |
Why?
|
| Phenotype | 3 | 2017 | 689 | 0.070 |
Why?
|
| Pyrazoles | 2 | 2025 | 80 | 0.070 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 32 | 0.070 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2009 | 28 | 0.070 |
Why?
|
| Actins | 1 | 2009 | 99 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2009 | 89 | 0.070 |
Why?
|
| Pancreatic Stellate Cells | 2 | 2020 | 6 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 646 | 0.070 |
Why?
|
| Materials Testing | 1 | 2008 | 89 | 0.070 |
Why?
|
| Terbium | 1 | 2007 | 2 | 0.070 |
Why?
|
| Europium | 1 | 2007 | 3 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 48 | 0.070 |
Why?
|
| Nanotubes | 1 | 2007 | 15 | 0.070 |
Why?
|
| Phosphates | 1 | 2007 | 33 | 0.070 |
Why?
|
| Nanostructures | 1 | 2008 | 64 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 614 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 93 | 0.060 |
Why?
|
| Endoplasmic Reticulum | 2 | 2020 | 80 | 0.060 |
Why?
|
| Microscopy, Confocal | 3 | 2013 | 113 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2010 | 489 | 0.060 |
Why?
|
| Time Factors | 2 | 2011 | 1619 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2018 | 203 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2013 | 524 | 0.060 |
Why?
|
| GTP Phosphohydrolases | 1 | 2005 | 19 | 0.060 |
Why?
|
| Quinolines | 1 | 2025 | 35 | 0.060 |
Why?
|
| Guanosine Triphosphate | 1 | 2005 | 29 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 29 | 0.060 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2005 | 14 | 0.060 |
Why?
|
| Zinc Fingers | 1 | 2005 | 26 | 0.060 |
Why?
|
| Cell Separation | 1 | 2005 | 57 | 0.060 |
Why?
|
| Vesicular Transport Proteins | 1 | 2005 | 34 | 0.060 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2025 | 40 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2005 | 68 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 102 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2005 | 43 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 233 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2004 | 28 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2005 | 128 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 292 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2024 | 15 | 0.050 |
Why?
|
| Lysophospholipids | 1 | 2024 | 51 | 0.050 |
Why?
|
| Thrombosis | 1 | 2005 | 155 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2004 | 79 | 0.050 |
Why?
|
| Plant Bark | 1 | 2002 | 2 | 0.050 |
Why?
|
| Diospyros | 1 | 2002 | 2 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2002 | 16 | 0.050 |
Why?
|
| Caspase 8 | 1 | 2002 | 10 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 697 | 0.050 |
Why?
|
| DNA Polymerase III | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lac Operon | 1 | 2002 | 4 | 0.050 |
Why?
|
| Exodeoxyribonuclease V | 1 | 2002 | 3 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2002 | 58 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2004 | 103 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 24 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2022 | 31 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 1057 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2002 | 45 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 83 | 0.040 |
Why?
|
| Static Electricity | 2 | 2013 | 35 | 0.040 |
Why?
|
| Gene Expression | 2 | 2013 | 418 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2021 | 5 | 0.040 |
Why?
|
| Autophagy-Related Proteins | 1 | 2021 | 9 | 0.040 |
Why?
|
| Biological Assay | 1 | 2021 | 34 | 0.040 |
Why?
|
| Insulin | 1 | 2022 | 325 | 0.040 |
Why?
|
| Inflammation | 1 | 2005 | 672 | 0.040 |
Why?
|
| Protein Domains | 1 | 2020 | 53 | 0.040 |
Why?
|
| Cystathionine gamma-Lyase | 1 | 2019 | 7 | 0.040 |
Why?
|
| Male | 4 | 2013 | 14126 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 417 | 0.040 |
Why?
|
| Sulfurtransferases | 1 | 2019 | 11 | 0.040 |
Why?
|
| Serine | 1 | 2019 | 51 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2019 | 20 | 0.040 |
Why?
|
| Liposomes | 1 | 2020 | 145 | 0.040 |
Why?
|
| Nitrobenzoates | 1 | 2019 | 7 | 0.040 |
Why?
|
| Pyrans | 1 | 2019 | 8 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 490 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 101 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 553 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2019 | 139 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 97 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2002 | 505 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 117 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 158 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 790 | 0.030 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 29 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 65 | 0.030 |
Why?
|
| DNA Primers | 2 | 2010 | 147 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Sp1 Transcription Factor | 1 | 2015 | 17 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 66 | 0.030 |
Why?
|
| rhoC GTP-Binding Protein | 1 | 2015 | 1 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 34 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 137 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 191 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 94 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 462 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 106 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 103 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 209 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 111 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 30 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 10 | 0.020 |
Why?
|
| Vimentin | 1 | 2013 | 28 | 0.020 |
Why?
|
| Cadherins | 1 | 2013 | 27 | 0.020 |
Why?
|
| Body Fluids | 1 | 2013 | 18 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2013 | 29 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 156 | 0.020 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 39 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 133 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 453 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 13 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 23 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Morpholinos | 1 | 2012 | 3 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 60 | 0.020 |
Why?
|
| Heat-Shock Response | 1 | 2012 | 13 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2012 | 21 | 0.020 |
Why?
|
| Light | 1 | 2013 | 119 | 0.020 |
Why?
|
| Proteomics | 1 | 2014 | 200 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2012 | 58 | 0.020 |
Why?
|
| Embryo, Nonmammalian | 1 | 2012 | 25 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 152 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 54 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 39 | 0.020 |
Why?
|
| Antimalarials | 1 | 2012 | 25 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2012 | 45 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2012 | 72 | 0.020 |
Why?
|
| Antibodies, Immobilized | 1 | 2011 | 4 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 104 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 228 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2011 | 54 | 0.020 |
Why?
|
| Folate Receptor 1 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2012 | 247 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 178 | 0.020 |
Why?
|
| SNARE Proteins | 1 | 2010 | 6 | 0.020 |
Why?
|
| Carbocyanines | 1 | 2010 | 10 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2010 | 65 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2011 | 264 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 49 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2009 | 46 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2009 | 32 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 33 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2009 | 92 | 0.020 |
Why?
|
| Osteoblasts | 1 | 2009 | 39 | 0.020 |
Why?
|
| Quinpirole | 1 | 2009 | 1 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2009 | 7 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2009 | 37 | 0.020 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2009 | 22 | 0.020 |
Why?
|
| Phosphotyrosine | 1 | 2009 | 18 | 0.020 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 7 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 131 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 589 | 0.020 |
Why?
|
| Salts | 1 | 2008 | 12 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 163 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2009 | 129 | 0.020 |
Why?
|
| Immunoconjugates | 1 | 2008 | 21 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 381 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2007 | 99 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 2442 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 2877 | 0.010 |
Why?
|
| Intracellular Space | 1 | 2005 | 12 | 0.010 |
Why?
|
| NIH 3T3 Cells | 1 | 2005 | 44 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 90 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 74 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 58 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2004 | 9 | 0.010 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2004 | 14 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 2004 | 36 | 0.010 |
Why?
|
| Luciferases | 1 | 2004 | 54 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 86 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 187 | 0.010 |
Why?
|